Supriya Announce Agreement To Market Plasma Nutrition’s IoProtein In India

Mumbai : API company Supriya Lifescience has announced a recent collaboration with Plasma Nutrition, a US-based nutrition company located in Delaware.

The strategic partnership involves an exclusive technology licensing agreement, granting Supriya Lifescience the sole rights for manufacturing and marketing Ingredient Optimised Protein (ioProtein) in India.

The primary purpose of this collaboration is to bring the optimised protein into the Indian market. ioProtein is a patented process (patent pending in the US) This revolutionary protein powder is designed for use as protein supplements and boasts a significant advantage, and it is highly bioavailable. This means that higher amounts of proteins are absorbed quickly by the body, providing consumers with a more effective and efficient protein supplement.

During the term of the agreement, Supriya Lifescience will lead the manufacturing and marketing of ioProtein in India. This marks the introduction of a new category of protein powders in the Indian market, and it is relatively healthier compared to other popular protein powders available through various gyms, general stores, and digital marketing channels.

“We are thrilled to be the exclusive partner of Plasma Nutrition, in introducing the innovative ioProtein to the Indian market,” said Dr Saloni Wagh, Executive Director at Supriya Lifescience.

“This strategic partnership represents our commitment to providing high-nutrition solutions to consumers in India. With ioProtein’s high bioavailability and its unmatched advantage, we are confident that the ‘IO’ technology will revolutionise the nutrition industry and become the preferred choice for health-conscious individuals,” Dr Wagh added.

“We are excited to collaborate with Supriya Lifescience and bring our patented ioProtein technology to India,” said Chris Flynn-Rozanski, co-founder & CEO at Plasma Nutrition.

“India’s rapidly growing demand for protein supplements present an excellent opportunity for us to introduce this highly bioavailable protein powder, which has already been well-received in other markets. We believe this partnership will create a new standard for protein supplementation in India,” Flynn-Rozanski said.

Related Posts

  • Pharma
  • March 13, 2025
  • 99 views
Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma

A study linking Indian-made generic drugs to a higher risk of serious side effects in the US has drawn backlash from the industry’s most influential lobby group, as India moves…

  • Pharma
  • March 13, 2025
  • 84 views
Indian Pharma market to expand by 8-9 percent in FY 26: Report

New Delhi: Indian pharmaceutical market is projected to see a growth of 8-9 per cent year-on-year in FY26 as per the recent report by India Ratings and Research (Ind-Ra). The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma

Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma

Indian Pharma market to expand by 8-9 percent in FY 26: Report

Indian Pharma market to expand by 8-9 percent in FY 26: Report

India’s Pharma Exports Face Tariff Hurdle amidst Trade Talks with the U.S.

India’s Pharma Exports Face Tariff Hurdle amidst Trade Talks with the U.S.

ED arrests two for trafficking banned drugs to US citizens

ED arrests two for trafficking banned drugs to US citizens